CRNX Crinetics Pharmaceuticals, Inc.
Price Chart
Executive Summary
Crinetics presented positive Phase 2 CAH data at ENDO 2026 showing atumelnant reduced androstenedione by 67% at week 12 while enabling 88% of patients to reach physiologic glucocorticoid doses. New Phase 1b/2a data in ACTH-dependent Cushing's syndrome also showed rapid cortisol normalization. Management is advancing atumelnant to Phase 3 CALM-CAH trial which is already enrolling.
Actionable Insight
Positive Phase 2 data with strong biomarker reductions and GC-sparing effect increases probability of Phase 3 success in classic CAH. Monitor enrollment updates and any regulatory feedback on Phase 3 design. ADCS data is early but adds optionality. Watch for potential partnership or financing given advancing pipeline costs.
Key Facts
- Mean A4 reduction of 67% from baseline at week 12 in Cohort 4 (80 mg morning dosing with GC reduction)
- 88% of Cohort 4 participants (7/8) achieved physiologic daily GC dose at week 12
- Atumelnant 40-120 mg once daily produced -58% to -80% A4 reductions across all cohorts 1-3 without GC reduction
- Phase 1b/2a ADCS data showed rapid lowering of early morning cortisol and UFC normalization in 3/6 participants at 40 mg dose
- Atumelnant advancing to Phase 3 CALM-CAH trial which is already enrolling patients
- No treatment-related severe or serious adverse events reported across any dose level
Financial Impact
No financial figures provided; Phase 2 data readout supports atumelnant's advancement to Phase 3, de-risking the program for a $3.6B market cap biotech with one approved product (PALSONIFY) and pipeline value tied to atumelnant
Risk Factors
- Phase 3 trials may fail to replicate Phase 2 biomarker results on primary endpoints
- Adrenal insufficiency AEs in ADCS trial require careful management and could limit commercial uptake
- Competing therapies for CAH (e.g., Eton Pharmaceuticals' chronocort) could limit market share
- Crinetics has $3.6B market cap with only one approved product — pipeline success is critical
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3311470 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 14, 2026
4d ago
|
Press Release
| $35.12 $35.00 | ▼ −0.34% | ▲ +0.25% | $35.75 (+1.79%) |
|
Jun 14, 2026
4d ago
|
Press Release
| $35.12 $35.00 | ▼ −0.34% | ▲ +0.25% | $35.75 (+1.79%) |
|
May 7, 2026
6w ago
|
8-K
| $37.48 $36.55 | ▼ −2.48% | ▼ −2.71% | $35.75 (−4.62%) |
|
Apr 10, 2026
9w ago
|
8-K
| $38.66 $39.75 | ▲ +2.82% | ▲ +1.61% | $35.75 (−7.53%) |
|
Apr 8, 2026
10w ago
|
Press Release
| $39.63 $39.44 | ▼ −0.48% | ▼ −0.42% | $35.75 (−9.79%) |
|
Mar 12, 2026
14w ago
|
Insider Cluster
| $36.51 $37.49 | ▼ −2.68% | ▼ −3.28% | $35.75 (+2.08%) |
|
Feb 26, 2026
16w ago
|
8-K
| $41.10 $40.68 | ▼ −1.02% | ▼ −1.08% | $35.75 (−13.02%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access